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Introduction
Th  e quasi-neoplastic nodular palmar ﬁ  bromatosis  [1] 
called Dupuytren’s disease (DD) often causes permanent 
ﬂ   exion contracture of the metacarpophalangeal and 
proximal interphalangeal joints of the digits [2,3] 
(Figure 1), leading to loss of function, deformity of the 
hand, and permanent contracture of the involved digits 
[2,4]. Although DD does not metastasize [5], it may 
invade locally within the palmar aponeurosis of the hand 
(sparingly supplied with blood vessels) and it is progres-
sive with a high rate of recurrence after surgical excision 
[6], often requiring amputation of the aﬀ  ected digit [7-9]. 
Th   e three stages of DD growth (proliferative, involutional, 
and residual) appear to involve dysdiﬀ   er en tiation  into 
myoﬁ  broblasts [10-12]. DD is associated with abundance 
of collagen, ﬁ  bronectin, integrins, cytokines and many 
other growth factors [2,7,13-15], as well as altered 
expression of several genes [16-25], but unlike the 
involve  ment of known oncogenes and suppressor genes 
in cancer development [26], our knowledge of the exact 
aetiopathogenesis of DD remains poor despite signiﬁ  cant 
understanding of its biology.
Systems biology combines mechanistic modelling with 
quantitative experimentation in studies of networks 
[27-34] and aims at understanding how the interaction of 
multiple components within a cell, tissue, organ or 
indeed individual leads to much of biological function 
and obfuscates correlations with single genes. Systems-
level approaches have begun to help comprehension of 
network control, (dys-)regulation, and function [35-38]. 
Th   is has improved the understanding of certain disorders 
[39], and has provided new rationales for drug discovery 
[40-42]. Th  e complex biology of DD may constitute an 
invitation to a systems level approach. In this review, we 
outline such an approach.
Dupuytren’s disease and its many faces
Histopathology
Clinical examples of ﬁ   brosis include renal interstitial 
ﬁ  brosis [43], scleroderma [44], sarcoidosis [45], idiopathic 
pulmonary ﬁ  brosis [46], retroperitoneal ﬁ  brosis [47] and 
DD [48]. DD tissue shows increased deposition of 
collagen III relative to collagen I and increased levels of 
collagen hydroxylation and glycosylation [49]. DD is 
thought to arise either from a defect in the wound repair 
process or from an abnormal response to wounding. Th  e 
presence of immune cells and related phenomena in DD 
tissue suggests DD may be immune-related [50-53]. 
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of several networks rather than of a single gene, 
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© 2011 BioMed Central LtdCellularity (quantiﬁ  ed as the cellular density) of the DD 
nodules (see below) is indicative of the activity of the 
disease [4]. DD has been classiﬁ  ed into three stages co-
existing in the same specimen, that is, proliferative, 
involutional and residual, further subdivided into the 
essentially ﬁ  brous nodules, reactive tissue, and residual 
tissue. It contains two structurally distinct ﬁ  brotic ele-
ments: the nodule is a highly vascularised tissue contain-
ing many ﬁ  broblasts, with a high percentage being recog-
nised as myoﬁ  broblasts due to their expression of the α-
smooth muscle actin; and the cord is relatively avascular, 
acellular, and collagen-rich with few myoﬁ  broblasts. Th  e 
nodule may develop into the cord as the disease pro-
gresses over time or the two structures represent inde-
pen  dent stages of the disease. Macroscopically, neither 
the deep retinacular tissue that includes the transverse 
palmar ligament or fascia, also known as ‘Skoog’s ﬁ  bres’, 
nor the ﬁ  brous  ﬂ   exor tendon sheaths appear to be 
involved in DD. Other areas are aﬀ  ected macroscopically 
but at irregular depth and distribution, with the more 
superﬁ   cial layers and ulnar side of the palm being 
aﬀ  ected most.
Th  e specialised mesenchymal cells expressing smooth 
muscle α-actin may explain the contractility observed in 
DD [11,54-56]; they resemble the myoﬁ  broblasts  of 
granulation tissue thought to be responsible for contrac-
tion during wound healing. Th   e Dupuytren myoﬁ  broblast 
synthesizes ﬁ  bronectin, an extracellular glycoprotein that 
connects myoﬁ   broblasts and connects them to the 
extracellular stromal matrix through an integrin.
According to genome-wide gene expression proﬁ  les, 
ﬁ  broblasts come in various subtypes [57], perhaps due to 
‘topographic diﬀ  erentiation’; that is, distinct phenotypes 
persisted  in vitro even when ﬁ   broblasts were isolated 
from the inﬂ  uence of other cell types [58]. Chang et al. 
[57] did not evaluate diversity or cell heterogeneity in 
DD. All of those evaluated had the morphology of 
elongated, spindle-shaped cells. Fibroblast cultures were 
uniformly positive for a mesenchymal immunoﬂ  uores-
cence marker, but negative for markers of epithelial, 
smooth muscle, endothelial, perineural, and histiocytic 
cells. Diﬀ   erent passages of the same ﬁ  broblast  culture 
clustered with each other, indicating that their in vitro 
phenotypes were stable. Several components implicated as 
modulators of transdiﬀ  erentiation of DD ﬁ  broblasts into 
myoﬁ   broblasts have been reported [59-69]. Among the 
cytokines, transforming growth factor-β is thought to be a 
signiﬁ   cant inducer of myo  ﬁ  broblast  transdiﬀ   er en tiation 
because of its ability to up-regulate α-smooth muscle actin 
and collagen in ﬁ  broblasts, both in vivo and in vitro [65].
Genetics
A study performed in a ﬁ  ve generation Swedish family 
suggested that DD was inherited in an autosomal domi-
nant pattern [70]. Linkage analysis implicated a single 
region of approximately 6 cM between markers D16S419 
Figure 1. Diff  erent stages of Dupuytren’s disease progression. Stage A generally starts as a small lump in the palm of the hand, often just under 
the digit on the palmar crease. In stage B the disease spreads up the fascia and into the fi  ngers, leading to the development of a cord. In stage C the 
disease spreads up the fi  ngers, eventually creating a tight cord such that the fi  ngers are forced to progressively bend, and are unable to straighten, 
eff  ecting an irreversible contracture. Reproduced with consent from Bayat et al. [6].
Stage C Stage B Stage A
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>1.5. Genotyping of four siblings aﬀ  ected by the disease 
but from another branch of the family together with the 
use of additional microsatellite markers produced a 
maximal LOD score of 3.2 (for D16S415), with four other 
markers producing LOD scores >1.5. When a disease is 
dominant, it is likely to be caused by a single allele of a 
single gene, and by the molecule it encodes. From this 
perspective, the above ﬁ  ndings would suggest that DD is 
a single gene disease. To date, however, linkage to a single 
gene has not been reported at a LOD that is much more 
signiﬁ  cant than the marginal value of 3 in this Swedish 
study and the penetrance in this study was incomplete. In 
addition, the disease develops at an advanced age, there 
are many more sporadic cases of DD, and there are few 
such families for which the genetic analysis has been 
performed. Indeed, other studies have shown association 
of the disease with other loci, including a positive 
association with HLA-DRB1*15 on chromosome 6 in 
Caucasians [71]. A study of 20 British DD patients with a 
maternally transmitted inheritance pattern demonstrated 
a mutation within the mitochondrial genome (mito  chon-
drial 16S ribosomal RNA region) in 90% of patients [72]. 
Th  e defective mitochondria generated abnormally high 
levels of free radicals and induced defects in apoptotic 
mechanisms.
Reactive oxygen species
A relation between localised ischaemia, reactive oxygen 
species (ROS) and DD was projected from a study in 
which palmar fascia from 10 DD individuals were 
subjected to 0 to 60 minutes of tourniquet ischaemia DD 
[73]. Th  e concentration of hypoxanthine was six-fold 
higher in Dupuytren’s palmar fascia compared to the 
palmar fascia from ten suitable control patients (having 
carpal tunnel decompression), implying that measuring 
metabolites directly in tissue could help understand DD. 
Xanthine oxidase catalyzes the removal of hypoxanthine, 
generating super oxide free radicals and hydrogen per-
oxide as by-products that would damage the peri  vascular 
connective tissue, which ﬁ   broblasts would attempt to 
repair. Upon addition of free radicals to ﬁ  broblast 
cultures from DD palmar fascia, lower concentrations of 
ROS stimulated ﬁ   broblast proliferation, explaining the 
observed increase in collagen type III [73]. Th  e hypo-
xanthine was more abundant in nodular areas than in the 
tight ﬁ  brous cords. We propose that microvessel narrow-
ing, leading to localised hypoxic conditions, may be one 
cause of DD, secondary to age, smoking and other 
environ  mental factors as discussed by Shih and Bayat [3].
Transcriptomics
Alterations of gene expression in Dupuytren’s nodules 
[25], Peyronie’s plaques [74], and cultured ﬁ  broblasts 
have been reported. Because of the complexity and 
hetero  geneity of the disease, we carried out a new trans-
criptome analysis, optimizing for unbiased experimental 
design, sample size and suﬃ     ciently large data sets by 
considering the nodule and the cord as two separate 
entities, and by adding a pathway oriented approach. We 
compared diseased Dupuytren tissue biopsies (both 
nodules and cords) with corresponding healthy tissue 
(the transverse palmar fascia adjacent to the diseased 
site) from the same patients as well as with proﬁ  les from 
the palmar fascia of individuals not aﬀ  ected by DD [18]. 
Th  e genes we conﬁ  rmed and established as altered in 
expression in DD [13,60] are involved in the immune 
response, angiogenesis, apoptosis, cell adhesion and cell-
matrix adhesion, cell cycle and proliferation, cell diﬀ  er  en-
tiation, transcription, development, signalling and signal 
transduction, protein synthesis and folding, oxygen trans-
port, and carbohydrate metabolism (Figure 2). A study 
comparing ﬁ   broblasts isolated from DD patients with 
those from controls found tens of genes to be altered at 
the mRNA expression level, although these diﬀ  ered 
between the two microarray platforms used. Th  e  down-
regulation of three of the genes was conﬁ  rmed  by 
quantitative PCR; these encode a proteoglycan, a ﬁ  bulin 
and type XV collagen alpha 1 chain [75]. Also using PCR, 
Ulrich and colleagues [76] found that DD tissue ampliﬁ  ed 
mRNA encoding one metalloprotease and two tissue 
inhi  bi  tors of metalloproteases. Th   e genes localised between 
markers D16S419 and D16S3032 encode hemoglobin α1 
and 2, cadherin 11 type 2, OB-cadherin (osteoblast), 
matrix metallopeptidase 2, periplakin, tryptase α/β1, and 
tryptase β2. Th   e transcriptomics results were therefore not 
particularly supportive of the early hypothesis that altered 
expression of a single autosomal gene on chromo  some 16 
is solely responsible for DD. Th  e observation that genes 
with fairly obvious functional connections to DD, such as 
those encoding metalloproteases, proteo  glycans and 
collagen components, have altered expres  sion brings home 
the message that even if the disease were to have a single-
gene origin, its aetiology is likely to involve multiple 
regulatory pathways and genes down  stream. Up to now 
the hunt for the single DD gene has not only failed but also 
weakened its own motivation; many genes, both upstream 
and downstream, may be involved in causing DD.
Proteomics
Th   e DD proteomics venture began in 2006 with the study 
of protein expression proﬁ  les in an attempt to identify 
potential disease biomarkers [77,78]. In one study, two-
dimensional gel electrophoresis was performed to extract 
proteins from diseased tissue (nodule and cord), the 
Skoog’s ﬁ  bres, and normal control tissues. MALDI-TOF-
MS (matrix-assisted laser desorption ionization time-of-
ﬂ   ight mass spectrometry) generated a peptide mass 
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however, the authors did not report names of identiﬁ  ed 
proteomic changes in their abstract. SELDI-TOF-MS 
(surface enhanced laser desorption/ionization time-of-
ﬂ  ight mass spectrometry) using Ciphergen’s SELDI-TOF-
MS Protein Biological System II (PBSII) ProteinChip 
reader [78] revealed several diﬀ  erentially expressed low 
molecular weight (<20 kDa) tissue proteins and identiﬁ  ed 
three disease-associated protein features (4,600.8 Da, 
10,254.5 Da, and 11,405.1 Da) that were elevated (5-, 12-, 
and 4-fold, respectively). Th  ree potential low molecular 
weight protein markers (p4.6DC, p1ODC, p11.7DC) for 
DD were identiﬁ   ed. An integrative proteomic-inter-
actomic approach [79] coupling two-dimensional gel 
electrophoresis with mass spectrometry compared the 
proteomic proﬁ  le of DD tissue with that of unaﬀ  ected 
patient-matched palmar fasciae tissue and found several 
proteins correlated with DD. Th  e ﬁ  ndings were used to 
create a protein-protein interaction network (inter  actome) 
map on the basis of the proposed interactions in the 
Human Interactome Map (HiMAP) [80] and the Search 
Tool for the Retrieval of Interacting Proteins (STRING) 
[81]; however, several proteins were added to ﬁ  ll gaps in 
order to yield a complete network, which then involved 
extra- and intracellular signalling, oxidative stress, cyto-
skeletal changes, and alterations in cellular metabolism. 
In particular, ERBB-2 and insulin-like growth factor 1 
receptor (IGF-1R) and the Akt signalling pathway 
emerged as novel components of pro-survival signalling 
in Dupuytren’s ﬁ   broblasts. One should exercise care, 
however, not to over-interpret these results, as they are 
partly based on inference from other protein interaction 
data obtained in diﬀ  erent contexts. In addition, increased 
activity of pathways need not involve increased protein 
levels [82] and increased pathway expression may be 
homeostatic rather than aetiological.
The dilemma: more or less data - less or more understanding
As more and more aspects associating with DD are 
revealed, we see less and less forest (understanding of the 
Figure 2. Cellular components, molecular functions and biological processes associated with Dupuytren’s disease as derived from gene 
expression studies [18] using Gene Ontology.
Biological processes Biological processes
Cellular component
Molecular Function
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the disease were set in motion by a single genetic factor, 
its aetiology would involve many diverse processes such 
that DD will be co-determined by the many factors that 
regulate those processes. If indeed the networks govern-
ing diﬀ  erentiation of normal ﬁ  brocytes of the palm of the 
hand are perturbed irreversibly so that they diﬀ  erentiate 
into muscle-like tissue without the proper controllers of 
contraction and relaxation, then diﬀ  erent sets of genetic 
perturbations could lead to DD. In this context DD may 
be much like cancer [39].
Th  e dilemma is that although we now have an un-
precedented set of methodologies for the identiﬁ  cation 
and analysis of all the molecules in living cells, that 
methodology alone is not enough. We need something 
substantially more to understand how all those molecules 
interact to create functional networks. Seeing more 
mole  cules may not help our understanding; seeing the 
connections between them and more mechanism might.
Systems biology disease versus molecular disease
Th   e disease in Figure 3a may seem to depend on a single 
molecule (gene) only, or at least that is how it is often 
conceived. But of course, a disease cannot depend on a 
gene (if deﬁ  ned as the corresponding DNA sequence) 
alone: it will depend on its gene product (F in Figure 3a), 
and in fact on the molecular function of the latter. For 
instance, a muscular dystrophy could result from a 
mutation in the gene encoding myosin, the molecular 
function of which is muscle contraction. If that muscular 
dystrophy were only found when the myosin gene has 
been mutated and if the severity of the disease was not 
inﬂ  uenced by other factors, then that muscular dystrophy 
would be a single-gene disease. In actuality there are 
many diﬀ   erent genetic lesions that lead to similar 
muscular dystrophies, including lesions in mitochon-
drially encoded genes [84]. A better candidate for a 
mono-gene disease may be phenylketonuria, an inherited 
(autosomal recessive) metabolic disease that is largely 
due to mutations in the phenylalanine hydroxylase (PAH) 
gene [85]. However, its therapy (dietary restriction) 
shows that the disease can be inﬂ   uenced by external 
factors, mutations in genes involved in the synthesis of a 
cofactor of the phenylalanine hydroxylation reaction also 
lead to the disease, and there are multiple alleles of the 
PAH gene that confer diﬀ  erent severities. Hence, even 
this disease exhibits characteristics of systems biology 
diseases.
Most diseases have multiple genes associated with 
them. Such diseases might be considered to be a group of 
single-gene diseases; that is, many diﬀ  erent diseases each 
being caused by a diﬀ  erent single gene lesion, but all with 
similar phenotypes [86]. Th   is would explain the asso  cia-
tion of multiple genes with the disease. In the case of a 
group of single gene diseases, no other faulty molecules 
should be important for that individual disease and no 
other gene changes (for example, polymorphisms) or 
conditions (for example, diet) should inﬂ  uence  the 
disease severity. Notably, a single patient’s transcriptome 
should then show only changes in the single molecular 
culprit and not in other factors controlling the network 
leading to the disease; and in the transcriptomes of 
diﬀ  erent patients suﬀ  ering from the same disease group, 
that single molecular culprit should be diﬀ  erent. For DD 
this is not what is observed (see above). As illustrated in 
Figure 3b, in a systems biology disease the function that 
is compromised depends cooperatively on a number of 
pathways, the functioning of each of which again depends 
on many cooperating molecular factors. In systems 
biology diseases one would typically ﬁ  nd  multiple 
changes in the transcriptome or proteome of each 
patient, diﬀ  ering between individual patients but such 
that all have a very similar disabling eﬀ  ect on network 
function. Identifying a disease as a systems biology or 
network disease does not dispel molecules from its 
pathology: molecules are always involved. Th  e issue is 
whether the change in networking of the molecules is 
crucial for the disease, that is, whether the disease is 
more a consequence of faulty networking than of an 
individual malfunctioning molecule.
What diﬀ   erence should this all make for research, 
diagnosis and therapy? Th  e answer is straightforward: 
when dealing with a network disease, one should deal 
with the network; when dealing with a molecular disease, 
one should concentrate on the molecule. For systems 
biology diseases, transcriptome patterns should be 
mapped onto the known cellular pathways, network 
ﬂ  uxes, and the disease. Th   e concept ‘candidate pathway’ 
or even ‘candidate network’ should be substituted for 
‘candidate gene’. In addition, one should investigate at the 
proteome, metabolome, and functional levels [87], and 
not each independently but all together, and then one 
may need to examine multiple network functions 
(Figure 4). Malignant cancer, for instance, may involve 
proliferation, lack of apoptosis, metastasis and multiple 
drug resistances.
Is Dupuytren’s disease a single-molecule or a systems 
biological disease?
DD has been identiﬁ  ed as a disease inherited in an auto-
somal dominant pattern [70] (and see above). It was 
linked to a single 6cM region on chromosome 16. Th  is 
would suggest that all DD patients should have a 
mutation in this part of their genome, and that trans-
criptomes of DD patients should be altered in terms of 
the level of the transcripts encoded by this part of the 
genome or in terms of the coding sequence of one of 
those transcripts. However, the dominance was 
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Swedish family. Th   is suggests that the genes on chromo-
some 16 are only dominant when other genes in the 
genome are of certain allelic forms. Moreover, in many 
other cases the expression levels of many other mRNAs 
were changed, although it remains to be analyzed 
whether in those studies there was always a change in 
mRNAs from the 6 cM region on chromosome 16. In our 
own studies, DD nodule transcriptomes of individual 
patients have all exhibited multiple changes in mRNA 
levels, and although these changes overlapped, they were 
not identical between individuals. Th   e proteome did not 
point to a single causative protein either. Th  e  functional 
studies pointed to myoﬁ  broblast enrichment, although 
not clearly as the sole cause, and neither was a causal 
relationship between a gene on chromosome 16 in the 
6 cM region and diﬀ  erentiation of myoﬁ  broblasts estab-
lished. Th   is all shows that DD is not a single-gene disease 
and suggests that it is not just a group of pure single-gene 
diseases either. It is much more likely to be a systems 
biology disease.
Treatment
Surgical intervention is still the current mainstay of 
treatment for DD, usually involving fasciotomy, fasciec-
tomy or dermofasciectomy [88]. A variety of non-opera-
tive techniques have been practiced but have failed to 
give long-lasting beneﬁ   ts. More recently, clinical 
Figure 3. Molecular versus systems biological disease. (a) In the molecular, or single-gene disease, a mutation in or around a piece of DNA 
causes a change in function of the gene product F. F is solely responsible (or the rate limiting step) for the physiological function that is impaired 
in the disease, or for the pathology itself. (b) In the systems biological or network disease, the biological function that is impaired in the disease, or 
the new pathological function, depends on many factors (called Z here) at the same time. Factors Z themselves depend on many other factors, on 
genes and environmental (for example, nutritional, hormonal, age) factors, and ultimately even on the development of the pathology itself. In terms 
of transcriptomics, changes in any factors shown could correlate somewhat with the disease, in either type of disease. In the molecular disease 
(a), however, the correlation between the disease and changes in the single causative disease gene should be 100%. When, as in systems biology, 
the cause-eff  ect relationships are investigated, the correlations should be time- and perturbation-dependent and consistent with the network 
drawn (for example, a deletion of Y might not aff  ect the disease totally, but should destroy the causal correlation between gene 2 and disease). The 
systems biology paradigm is not soft, however, as in that case the correlation between disease and network state should be 100%.
(a) (b)
Gene  Gene  Gene  Disease
2 1 3 gene
X X X X X
environment
F
Y Y
function
Y Y environment
function
Z Z
Z Z
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clostridial collagenase injections, have shown encourag-
ing results in some DD patients [89,90], but long-term 
follow-up results are required before this can be 
advocated as standard procedure in place of surgery.
Conclusion
Since association of DD with a single gene is inconclusive, 
the present mainstream research paradigm may be 
unlikely to lead to a full understanding of it. Th  e  experi-
mental data appear to be more consis  tent with DD being 
a systems biology disease. Th   erefore, a diﬀ  erent approach 
to the disease should be considered; analysis, diagnosis 
and therapy should target pathways rather than genes or 
their products. Th   e concept of a ‘candidate gene’ should 
be replaced with that of ‘candi  date pathway(s)’. Studies 
should be aimed at elucidating cause-eﬀ  ect chains, rather 
than disease corre  lations. From the experimental data, 
alterations in path  ways should be inferred. Using trans-
genic and antisense approaches in cell lines, these path-
way alterations should then be induced and the predicted 
development into a DD cellular phenotype tested. Th  e 
pathways are expected to be integrals of gene expression, 
signalling and metabolic networks, as should be the 
approach and data analysis.
A hypothesis-driven systems biology would be based 
on a priori observations in human, in vitro or in vivo 
(linkage and expression studies, for example), or on 
knowledge of related diseases (such as plantar ﬁ  broma-
tosis, peyronies, musculo-aponeurotic ﬁ  bromatosis and 
even keloid disease). Inter-relationships would be sought 
between hypothesized underlying mechanisms governing 
these ﬁ  brotic disorders and physiological changes pre-
dicted based on molecular and environmental changes 
impacting on those mechanisms. Th  is could then be 
extended to understand inter- versus intra-individual 
variability. Altering the networks using multiple mole  cu-
lar inter  ven  tions in a tissue culture model system for DD 
would enable the hypotheses to be tested.
Such an approach should also help put into perspective 
existing inconclusive discoveries and maximize the 
utilization of data obtained from molecular approaches 
Figure 4. The complex reality of most diseases, as proposed here for Dupuytren’s disease. Dupuytren’s disease (DD) depends on the 
simultaneous occurrence of several malfunctions, each of which is controlled by a network of internal and environmental factors. These networks 
also have roles in processes (Z) other than just DD development. In this example of a systems biology disease, only careful dissection of the 
network changes determined by accurate experiments that involve (i) diff  erent points in time/progression of the disease and diff  erent genetic 
and environmental backgrounds, (ii) quantitative experimentation at the transcriptomic, proteomic, metabolomic and functional levels, and (iii) 
computation-assisted analysis and experimental design can lead to understanding of the disease and rational and optimally eff  ective therapies. This 
fi  gure is for illustrative purposes only and the precise network structure has yet to be fully determined.
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Page 7 of 12Figure 5. A proposed information fl  ow for Dupuytren’s disease research versus normal fi  broblast biology research. In the top-down 
branch of the systems biology approach, data maps generated by large scale experiments fi  rst need to be annotated and subjected to statistical 
analysis in order to extract biologically relevant information. That information should then be used to generate hypotheses concerning patterns 
of molecular behaviour or dynamic parameters of the networks. Phenomenological or partly mechanistic mathematical modelling can already 
help here to weed the impossible from the possible and to enable one to put multiple complex interactions into single testable hypotheses. Then, 
predictions can be made and tested. This may spiral through iterations of top-down systems biology into an ever improving set of hypotheses that 
may become more and more mechanistic. A bottom-up systems biology branch of the research may begin with proposed mechanisms (such as 
stimulation of fi  broblast growth because of enhanced reactive oxygen species production) and develop mathematical models of these in order 
to assist with experimental design. By spirally testing and adjusting the hypothesis this will ultimately lead to a hypothesis that is better and better 
tested and involves more and more of the network. At each step, data will be consolidated, reducing the amount of unnecessary information while 
increasing their accuracy, quality and usefulness to improve and generate stronger models of the DD cell. A metabolic or signalling network can 
then be represented in silico and its properties studied using computer-simulated perturbations. For instance, the fl  ux balance model could be 
applied to predict the behaviour of metabolic networks upon perturbation of the optimised metabolites within a metabolic pathway.
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Page 8 of 12from molecular biology, perhaps in the sense of a live 
model repository [91]. Indeed, omics experiments gener-
ate heterogeneous data and metadata torrents. Systems 
biology modelling would serve as a way to organize the 
data rationally and eﬃ     ciently. Emerging standard lan-
guages, such as the Systems Biology Markup Language 
(SBML) [92], Cell Markup Language (CellML) [93], Cell 
System Markup Language (CSML) [94], Biological 
Pathway Exchange (BioPAX) [95] and Systems Biology 
Graphical Notation (SBGN) [96], and modelling tools 
such as COmplex PAthway SImulator (COPASI) [97], 
Cytoscape [98] and Pathway databases (for example, 
Ingenuity pathway analysis software) facilitate data repre-
sentation and inter-operability from leading multidisci-
plinary research groups [99]. Additionally, the Java Web 
Simulation (JWS) facility, which quality controls kinetic 
models and puts them into a live repository, enables 
through-web experimentation in silico for scientists naive 
with respect to modelling, although it is experiment-
dependent [100]. BioModels is a parallel model reposi-
tory not built for in silico experimentation but focusing 
on annotation [101].
If we are right, and the systems biology research 
paradigm is adopted, the rewards should be substantial: 
no longer will the data collected in this ﬁ  eld disappear 
into the diaspora of the experimental literature; they will 
be analyzed in terms of network models and, when infor-
mative, connected with proper data annotation [102]. 
Once the network hypotheses are proven, they will 
under  pin the development of new rational biomarker 
strategies, and become the starting point for potential 
therapeutic interventions and prophylaxis.
More concretely, even though myoﬁ  broblasts obtained 
from diﬀ  erent stages of DD may exhibit features that could 
trigger contraction and uncontrollable growth, neither the 
diversity of these cells nor the extent or nature of their 
local speciﬁ  city in situ with regard to diﬀ  er  entiation have 
been examined systematically. Remodel  ling of vascular 
connective tissue should be of funda  mental importance as 
DD progresses over time and the ability of that tissue to be 
remodelled could be an important factor in the develop-
ment of the disease. Matrix remodelling and matrix 
turnover are controlled by a complex network of cell-cell 
and cell-matrix inter  actions [103]. Mathematical model-
ling of these networks combined with targeted experimen-
tation should help deduce the net outcome of the balance 
between proliferative and degradative processes.
Together, genomics, transcriptomics, proteomics, ﬂ  ux-
omics, lipidomics, interactomics, glycomics and secret-
omics studies of bioﬂ  uids within the DD system have the 
potential to improve our understanding of the disease 
immeasurably [104-106]; however, the ‘together’ concept 
requires an integration that is only plausible through 
systems approaches.
Investigating this complex deforming ﬁ  bromatosis as 
part of a systems biology approach (Figure 5) will beneﬁ  t 
not only understanding of the speciﬁ  c diseased pheno-
types, but may also address the eﬀ  ects on the extracellular 
matrix and excreted by-products, and could oﬀ  er further 
suggestions for early diagnosis.
Recognition of DD as a systems biology disease should 
also aﬀ  ect therapy. Treatment need not target the reversal 
of a molecular event but rather return a network aﬀ  ected 
by a combination of molecular culprits (for example, 
resulting from single-nucleotide polymorphisms) to its 
normal state. Th  is return may be attempted by inter-
ventions in the network that may otherwise be unrelated 
to the molecular culprits. In this sense the recognition 
that DD is a network disease should increase the number 
of treatment options. More speciﬁ  cally, one should look 
at a number of intracellular networks (metabolic, signal 
transducing, or otherwise) aﬀ  ecting the disease and then 
consider treatment with combinations of existing drugs 
(and behavioural advice) that target all those networks. 
Th  e relative dosages should be optimized, allowing for 
the optimum to diﬀ  er between patients.
Abbreviations
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